A Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Five Different Doses of Inhaled Indacaterol (QAB149) Delivered Via the Single Dose Dry Powder Inhaler (SDDPI) in Patients With Persistent Asthma
Phase of Trial: Phase II
Latest Information Update: 20 May 2015
Price : $35 *
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary) ; Indacaterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis
- 27 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Nov 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 Oct 2013 New trial record